Be generous with treats whenever you’re taking photos or videos of your pets, especially if they’re showing off their best tricks. It won’t take them long to associate the camera with yummy treats…

DELRAY BEACH, Fla. (PRWEB)
July 06, 2020

Pets are usually the center of attention in families and now it’s time to share their cuteness with the world. Get those star quality shots with these quick tips.

To get the best photos and videos of pets, aim to film or photograph in natural lighting, either outside or by a window. Make sure the light source is shining on the pet from the front or just to the side, as lighting them from behind will result in a hazy silhouette. Avoid using flash, as it tends to light up the pet’s tapetums, the reflective layer in their eyes that helps them see in low-light conditions.

“Be generous with treats whenever you’re taking photos or videos of your pets, especially if they’re showing off their best tricks” says Larissa Schenck, Director of Marketing at 1-800-PetMeds®. “It won’t take long for them to associate the camera with yummy treats, and they’ll ham it up whenever they notice you’re recording them.”

Pet parents everywhere are invited to submit short video clips that show off their pet’s personality. Dazzle with your pet’s clever tricks, cutest candid moments, and funniest antics for a chance to be featured in a 1-800-PetMeds® upcoming video. Four winners will get a Furbo Dog Camera.

The 1-800-PetMeds® Superstar Pet Sweepstakes runs from July 6th, 2020 through July 31st, 2020. Everyone who enters from 12:01 AM Eastern Time (“ET”) July 6, 2020 to July 31, 2020 at 11:59 PM ET is eligible to win a Furbo Dog Camera. There will be four (4) winners total. To enter, visit the Superstar Pet Sweepstakes page and upload your cutest clip. Pet parents can also post the video on Twitter or Instagram using the hashtag #SuperstarPet.

About 1-800-PetMeds®

Founded in 1996, Petmeds.com is America’s Most Trusted Pet Pharmacy® providing fast, easy and helpful service to over ten million customers across the U.S. by delivering prescription and non-prescription medications and pet supplies for less, direct to the consumer through its 1-800-PetMeds® toll-free number, on the Internet through its website Petmeds.com, or with the 1-800-PetMeds® mobile app available for free at Google Play for Android and the App Store for iOS.

Share article on social media or email:

With this group of renowned physicians serving as our Clinical Advisory Board, they will help us achieve our goals and maintain the highest company standards while forging new paths and standards within the industry.

PHOENIX (PRWEB)
July 06, 2020

The innovators at Aesthetics Biomedical® (ABM), a leading aesthetics device and product development corporation are honored and excited to announce that Drs. Grant Stevens, Steven Dayan, Michael DeWolfe, and Stephen Ronan have been appointed to the company’s Clinical Advisory Board (CAB). These physicians are experts in the field representing aesthetics, plastic surgery, and dermatology.

The goal of the CAB is to bring together the most trusted plastic surgeons, dermatologists, and biomedical device and skincare treatment experts to provide clinical input into the company’s new product development, experience offerings, and clinical study design and execution. Collectively they bring their experience and market expertise to advise ABM’s senior leadership team on important trends within the industry and to help ensure the utmost integrity is incorporated into all aspects of the company’s clinical operations and product development.

“As a leader in innovation, we value the input and expertise of the experienced physicians working with patients on a daily basis. With this group of renowned physicians serving as our Clinical Advisory Board, they will help us achieve our goals and maintain the highest company standards while forging new paths and standards within the industry. We have meticulously selected this impressive team to continue to establish ABM’s leadership within the field of aesthetics” says MaryAnn Guerra, CEO of Aesthetics Biomedical®.

Each of these individuals bring tremendous talent and expertise to Aesthetics Biomedical’s Clinical Advisory Board:

Grant Stevens, MD, FACS, is the founder and medical director of Marina Plastic Surgery and the Marina Med Spa in Marina Del Rey, California. He is a Clinical Professor of Plastic Surgery at the University of Southern California, Chairman of the USC-Marina Aesthetic Surgery Fellowship and the Director of the USC Division of Aesthetic Surgery. He is a board-certified Diplomate of the American Board of Plastic Surgery and a Fellow of the American College of Surgeons and the International College of Surgeons. Dr. Stevens has authored more than 90 articles and chapters on aesthetic plastic surgery.

Steven Dayan, a facial plastic surgeon, professor and researcher has published over 120 articles in medical journals and 5 books. He is a NY Times and USA TODAY Best-Selling Author. His accolades include the American Medical Association (AMA) Foundation’s Leadership Award and “Top Doc” recognition by numerous organizations including Castle Connolly and U.S News & World Report as well as being ranked the #1 Aesthetic Physician in the USA by the peer voted Aesthetic Everything in 2016. As a founder of a Denova, medical research company, a medical marketing company, a skincare training center and a medical education company, he remains on the cutting edge of aesthetic products, thinking and education. He has authored 5 books. But it is in his role as an adjunct professor —teaching a popular undergraduate course: The Science of Beauty and Its Impact on Culture and Business – that his best-selling book Subliminally Exposed is based. He has authored 5 books. But it is in his role as an adjunct professor —teaching a popular undergraduate course: The Science of Beauty and Its Impact on Culture and Business – that his best-selling book Subliminally Exposed is based.

Michael DeWolfe, MD is a Board-Certified Plastic and Reconstructive Surgeon associated with a variety of Chicago hospitals. He serves patients in the Southport Corridor and throughout the Chicago land area. Dr. DeWolfe’s surgical expertise continues to be sought out by patients both nationally and internationally. Dr. DeWolfe earned his medical degree from the Medical University of South Carolina where he was President of the Alpha Omega Alpha Honor Society and received Salutatorian honors. He completed a residency in Plastic and Reconstructive Surgery at the University of Chicago Hospitals, followed by a fellowship in Microvascular Surgery specializing in head, neck, trunk, lower extremity and breast reconstruction. His comprehensive medical and aesthetic approach offers precise results and unparalleled quality of care. Dr. DeWolfe values the relationships he builds with patients and their families. He believes open communication is the key to a successful partnership. Whether treating a medical issue or an aesthetic need, Dr. DeWolfe utilizes the most advanced techniques to achieve superior results in a compassionate manner to provide the highest possible quality of care.

Stephen J. Ronan, MD FACS is an award-winning plastic surgeon performing thousands of surgery procedures every year in the Blackhawk Surgery Center, Stephen J. Ronan MD FACS, has been named one of the Top Plastic Surgeons in America by the nation’s leading providers of information on doctors. He was also voted Best in The Bay, and one of the Top 3 Hair Restoration Surgeons in America 2015, by Aesthetic Everything Beauty Network, a panel of industry leaders and fellow surgeons. From high fashion magazines like Glamour, to national TV appearances on The Doctors, Dr. Ronan is sought after by the media to provide expertise on the newest cosmetic innovations.

CAB members will also represent Aesthetics Biomedical® at industry events, conferences, drafting of scientific papers and participate in clinical trials.

ABOUT AESTHETICS BIOMEDICAL®: The aesthetic innovation company headquartered in Phoenix, Ariz., uniquely offering procedure and product enhancement, development, clinical indication, expansion, application optimization, FDA clearance expertise and worldwide distribution. Aesthetics Biomedical’s innovation center is a leader in breakthrough technologies and multiple source combination therapies for its clients, physician network and the aesthetic arena.

CONTACTS:

Marketing Contact: Sheldon Larson, CMO

Sheldon@AestheticsBiomed.com

Press Contact: Courtney Frappier, Senior PR Manager

CFrappier@AestheticsBiomed.com

Share article on social media or email:

Aesthetics Biomedical

Its critical to have these expert advisors, who are key opinion leaders in their fields, to keep the company focused on its core technology and principles of driving research-based innovation…

PHOENIX (PRWEB)
July 06, 2020

The innovators at Aesthetics Biomedical® (ABM), a leading aesthetics device and product development corporation are honored and excited to announce that Drs. Wendy Roberts, Zoe Draelos, Robert Kellar, Vivian Bucay, and Emil Tanghetti have been appointed to the company’s Scientific Advisory Board (SAB).

The goal of the SAB is to collaborate with the most trusted plastic surgeons, dermatologists, and biomedical device and skincare treatment experts to provide scientific research and input into the company’s new product development, experience offerings, and clinical study design and execution. Collectively they contribute to advise ABM’s senior leadership team on all aspects of the company’s clinical operations and product development.

Lawrence Rheins PhD, ABM’s Chief Scientific Officer states, “Its critical to have these expert advisors, who are key opinion leaders in their fields, to keep the company focused on its core technology and principles of driving research-based innovation, and provide support to our clinical/scientific team with direct access to clinicians, academicians, and industry veterans.”

“As innovators, we value the input and expertise of the experienced physicians working with patients on a daily basis. We have meticulously selected this impressive team for our Scientific Advisory Board to continue to establish ABM’s leadership within the field of aesthetics” says MaryAnn Guerra, CEO of Aesthetics Biomedical®.

Each of these individuals bring tremendous talent and expertise to Aesthetics Biomedical’s Scientific Advisory Board:

Wendy Roberts, MD – Dr. Wendy Roberts is a double board-certified dermatologist and the Founding Director of Dermatopathology of Loma Linda Division of Dermatology. She pioneered and developed Generational Dermatology™ which is a detailed system of age management. Dr. Roberts recent achievements include being the Physician Expert for season 1 of Chasing the Cure Live with Ann Curry, earning a spot on the cover of Dermatologist in October 2019, Moderator and Author of JDD Supplement Practical Applications for Medical and Aesthetic Treatment of Skin Of Color, and being the first and only female dermatologist to exclusively own her own meeting.

Zoe Draelos, MD – Dr. Zoe Draelos is a research and clinical board-certified dermatologist. She has a solo private practice in North Carolina and is the founder of Dermatology Consulting Services, PLLC. Dr. Draelos was elected Vice President of the American Academy of Dermatology. In addition to the 3rd edition of her Cosmetic Dermatology textbook currently under preparation, Dr. Draelos’ recent achievements include the Society of Cosmetic Chemists awarding her both the 2018 Maison de Nevarre award given to an individual who has contributed greatly through research for the advancement of Cosmetic Science followed by the inaugural Florence Wall Award in 2019 given to the most influential woman in Cosmetic Science.

Robert Kellar PhD – Dr. Robert Kellar is Founder and President of Development Engineering Sciences, LLC. He has over 19 years of experience in the development and regulatory approval of medical devices, cell-based products and tissue engineering. A PhD in Physiological Sciences from the Univ of AZ, he has served on multiple Scientific Advisory Boards in regenerative medicine. Recent accomplishments include 145 scientific abstracts, 35 peer-reviewed publications, and 6 issued US patents. As well as being awarded Arizona Business Magazine’s Healthcare 2019 Leaders Award, and the 2020 Research and Creative Activity (RCA), Northern Arizona University, “Most Significant Innovation in Technology Transfer of Commercialization” award.

Vivian Bucay, MD – Dr. Vivian Bucay completed her dermatology training at the University of Miami and the Baylor College of Medicine. She serves as volunteer faculty as Clinical Assistant Professor in the Department of Physician Assistant studies at the University of Texas Health Science Center and is faculty on several other continuing medical education initiatives in the US. In addition to lecturing nationally and internationally, and publishing papers in peer reviewed journals and writing book chapters for dermatology textbooks and publications. Dr. Bucay has also been recognized as a Texas Super Doctor yearly since 2004. She recognizes one of her greatest achievements, aside from her daughters, is surviving stage 4 melanoma in 2006-7.

Emil Tanghetti, MD – Dr. Emil Tanghetti graduated first in his class and received the Dean Warren medal for academic excellence. He is a fellow of the American Society for Laser Medicine and Surgery, and a member of the California Medical Association, the American Medical Association, and the American Academy of Dermatology. In just the last year, Dr. Tanghetti has had 13 articles published on topics including Rosacea, Acne, Psoriasis, and energy-based therapies. He’s also recently been invited to join Lasers in Surgery and Medicine as an associate editor, as well as editor for a special 2020 dermatology issue.

SAB members will also represent Aesthetics Biomedical® at industry events, conferences, drafting of scientific papers and participate in clinical trials.

ABOUT AESTHETICS BIOMEDICAL®: The aesthetic innovation company headquartered in Phoenix, Ariz., uniquely offering procedure and product enhancement, development, clinical indication, expansion, application optimization, FDA clearance expertise and worldwide distribution. Aesthetics Biomedical’s innovation center is a leader in breakthrough technologies and multiple source combination therapies for its clients, physician network and the aesthetic arena.

CONTACTS:

Marketing Contact: Sheldon Larson, CMO

Sheldon@AestheticsBiomed.com

Press Contact: Courtney Frappier, Senior PR Manager

CFrappier@AestheticsBiomed.com

Share article on social media or email:

www.actionbyacamp.us

“ACAMP is proud to release the A95™ respirator to the US market.” said Ken Brizel, CEO ACAMP

EDMONTON, Alberta (PRWEB)
July 06, 2020

US customers can now purchase ACAMP’s washable, reusable respirators with over 95% particle filtration efficiency to help prevent the spread of COVID-19. The A95™ respirator can be worn anywhere and is an excellent choice for travelers spending extended periods of time in confined spaces, such as aircraft or trains.

ACAMP developed its line of respirator products in April 2020 for the Canadian market, in response to seeing so many unprotected people shopping and travelling. The A95™ respirator and replacement filters, previously only available in Canada, are now available online to US customers at actionbyacamp.us/

A respirator is markedly different from paper or cloth masks as it creates a base-seal around the wearer’s nose and mouth which forces airflow primarily through the front filter. Respirators filter two ways: protecting wearers from inhaling the virus, and preventing wearers from exhaling it to loved ones and co-workers.

The A95™ filters provide 95% particle filtration efficiency, are washable and reusable, and the respirator can be easily adjusted for comfort and fit. The respirator body is made of thermoplastic and is available in one adult size at this time.

The A95™ respirator’s efficiency was tested against commercially available N95-rated models by the respiratory aerosol mechanics team at the University of Alberta Faculty of Engineering. They rated the ACAMP A95™ filters at similar levels of filtration efficiency as N95 filters.

Technical information, test results and videos can be found at actionbyacamp.us/

For interviews contact:

Ken Brizel

kbrizel@acamp.ca                        

780-468-2443

About ACAMP

Founded in Alberta, Canada in 2007, ACAMP is a unique industry-led advanced technology product development centre that entrepreneurs count on to move their innovation from proof-of-concept to manufactured product by providing access to multidisciplinary engineers, technology experts, unique specialized equipment, and industry acumen. ACAMP focuses on electronics hardware, firmware, software (ML/AI), sensors, and embedded systems. ACAMP is the only advanced technology product development group in Canada that provides a full range of support at each stage of the product development process. Offices in Edmonton and Calgary, ACAMP offers support to companies worldwide. For more information, please visit acamp.ca. A95™ is a trademark of ACAMP, Edmonton, Alberta, Canada.

Share article on social media or email:

The Innovative Practices Awards consistently recognize efforts in our community to push our technological boundaries further to advance life sciences research.

BOSTON (PRWEB)
July 06, 2020

Bio-IT World has announced the winners of the 2020 Innovative Practices Awards. Entries from Roche, Eli Lilly, Bristol-Myers Squibb, the University of Chicago, Massachusetts General Hospital, Mission: Cure, and the Pistoia Alliance were honored.

Since 2003, Bio-IT World has hosted an elite awards program, highlighting outstanding examples of how technology innovations and strategic initiatives can be powerful forces for change in the life sciences, from basic biomedical research to drug development and beyond.

“The Innovative Practices Awards consistently recognize efforts in our community to push our technological boundaries further to advance life sciences research. Sharing these collaborations offers opportunities for the whole community to emulate best practices and leapfrog current hurdles for future growth,” said Allison Proffitt, Editorial Director of Bio-IT World. “Although the 2020 Bio-IT World Conference & Expo has been moved to October, we couldn’t wait to share these well-deserving projects with our community.”

A panel of expert judges joined the Bio-IT World editors and Cambridge Healthtech Institute executives in reviewing detailed submissions from pharmaceutical companies, academic centers, government agencies, and technology providers. Five outstanding entries were named winners.

2020 Bio-IT World Innovative Practices Awards Winners

• 
  Bristol-Myers Squibb and the University of Chicago, Center for Translational Data Science nominated by BioTeam

The ability for researchers to find, access and share genomics data in order to maximize the potential of data-driven science is still a large challenge for pharmaceutical organizations. In late 2018, the Center for Translational Data Science at the University of Chicago released “Gen3”: a free, open source framework for creating a data commons. In 2019, IT for Translational Medicine at Bristol-Myers Squibb created “SiloBreaker,” a program with the mission to break down the barriers that exist between genomics data and scientists and create the conditions necessary to foster a collaborative genomics discovery ecosystem. BMS is the first pharmaceutical organization to leverage Gen3 to build its own internal data commons (“BMS Genomics Discovery Hub”).

• Center for Innovation and Bioinformatics, Neurological Clinical Research Institute, Massachusetts General Hospital

The SigNET Platform enables scientific collaboration, integration, analyses, and distribution of research data across studies and repositories. It generates Unique Clinical Research Identifiers (UCRIs) per Patient per Study per Disease, thus permitting collaboration and sharing in rare diseases, in which utilization of “standard” GUIDs may not be enough to protect identities of patients participating in multiple research projects. UCRIs allow aggregation and prevent duplication of patients’ records, enable integration/sharing of patient information originating in clinical/research silos, and allow automation of searches across multiple repositories. Such innovative approach and technology offer standardized, reliable, and secure way to collaborate across research continuum accelerating discoveries across academia, foundations, and the industry. Several pharma/biotech companies, government agencies, academic consortia, and disease foundations utilize SigNET in clinical trials/studies.

• Eli Lilly and Company nominated by EPAM Systems

As a 143-year-old company, Lilly has access to myriad high value data. The challenge Lilly faced was the ability to derive value from data in record time and in a cost-efficient manner. Lilly’s Research.Data Program is a solution that has helped the company overcome that challenge. By enabling the FAIR principles for information in a deep ecosystem of data products, discovery researchers and data scientists can now gain insights for portfolio decisions more quickly and efficiently than ever before: deliver all research data in a consistent, managed and sustainable environment where researchers find, access, interoperate and reuse data (FAIR); deploy integrated catalog, data dictionary, data lake, data pipelines, and secure application programmable interfaces that enable cost efficient delivery of data products; expose more than 100 data products to eight production applications used by hundreds of scientists worldwide; and accelerate science in discovery chemistry, biology and molecular innovation in key therapeutic areas including Diabetes, Immunology, Neuroscience and Oncology.

• Pistoia Alliance and Mission: Cure nominated by Elsevier

Elsevier and Pistoia Alliance organized a drug-repurposing datathon, with Cures Within Reach and Mission: Cure being the consulting organizations. The objective was to identify repurposable drug candidates for chronic pancreatitis—a rare disease that affects about 1 million people globally, and currently doesn’t have an approved treatment. Datathon participants used Entellect, an Elsevier data integration platform, to access Elsevier supplied datasets such as Reaxys Medicinal Chemistry, ResNet (aka PathwayStudio) and PharmaPendium. In addition, participants were able to incorporate third party datasets into Entellect to create a single, harmonized and linked dataset against which they applied machine learning and statistical techniques, from exploratory data analysis and data pre-processing, to feature engineering, model building, validation and comparison, and finally result visualization and model deployment. As a result, 4 drug candidates were identified in 30-60 days, then reviewed and approved by the expert panel, pending further clinical trials by Mission: Cure.

• Roche nominated by Linguamatics

The focus of the Roche research was to discover if social media, particularly patient blogs and forum, can provide a good substrate to develop clinical endpoints relevant to Parkinson’s disease patients. Being able to understand what matters most to patients and find unexpected insights into patient problems shapes clinical trials, e.g. by influencing design and outcome measures. Highly trusted social media sources (i.e. patient-focused communities) provided a robust substrate to analyze. From 24k verbatims downloaded and processed with Linguamatics NLP (Natural Language Processing), the Roche team extracted valuable data from ~450 posts. Ensuring that privacy issues were addressed, they were able to categorize the comments into symptom or impact categories. The study identified symptoms confirmatory of the clinical trial endpoints, and also added additional ones; and these specific recommendations have been added to the clinical disease model used in the clinical trial. Roche’s approach is an example of patient-centered drug development (an FDA initiative) and ensures that clinical disease models encompass patient needs.

Share article on social media or email: